| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tomography, X-Ray Computed | 85 | 2022 | 7551 | 4.540 |
Why?
|
| Lung Neoplasms | 68 | 2023 | 11538 | 3.280 |
Why?
|
| Diagnostic Imaging | 24 | 2021 | 1162 | 3.170 |
Why?
|
| Positron-Emission Tomography | 37 | 2022 | 2173 | 2.800 |
Why?
|
| Pleural Neoplasms | 13 | 2023 | 470 | 2.730 |
Why?
|
| Thoracic Neoplasms | 8 | 2021 | 337 | 2.180 |
Why?
|
| Mediastinum | 11 | 2022 | 268 | 2.040 |
Why?
|
| Mediastinal Neoplasms | 7 | 2022 | 423 | 1.750 |
Why?
|
| Mesothelioma | 10 | 2022 | 544 | 1.690 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 30 | 2023 | 5319 | 1.630 |
Why?
|
| Positron Emission Tomography Computed Tomography | 13 | 2022 | 833 | 1.600 |
Why?
|
| Fluorodeoxyglucose F18 | 25 | 2022 | 1226 | 1.580 |
Why?
|
| Pericardium | 6 | 2022 | 157 | 1.550 |
Why?
|
| Solitary Pulmonary Nodule | 7 | 2021 | 123 | 1.410 |
Why?
|
| Multimodal Imaging | 8 | 2015 | 550 | 1.400 |
Why?
|
| Thorax | 9 | 2022 | 213 | 1.370 |
Why?
|
| Tomography, Emission-Computed | 10 | 2011 | 310 | 1.240 |
Why?
|
| Lymphadenopathy | 3 | 2022 | 90 | 1.080 |
Why?
|
| Radiopharmaceuticals | 20 | 2022 | 1301 | 1.010 |
Why?
|
| Neoplasm Staging | 39 | 2022 | 13658 | 1.010 |
Why?
|
| Radiography, Thoracic | 14 | 2019 | 462 | 0.980 |
Why?
|
| Lung | 27 | 2022 | 3151 | 0.960 |
Why?
|
| Mediastinal Diseases | 2 | 2022 | 56 | 0.940 |
Why?
|
| Pulmonary Embolism | 6 | 2022 | 329 | 0.880 |
Why?
|
| Diagnostic Errors | 7 | 2021 | 509 | 0.870 |
Why?
|
| Image Interpretation, Computer-Assisted | 6 | 2021 | 592 | 0.860 |
Why?
|
| Diagnosis, Differential | 26 | 2019 | 4744 | 0.840 |
Why?
|
| Fat Necrosis | 1 | 2022 | 63 | 0.810 |
Why?
|
| Lung Diseases | 5 | 2018 | 717 | 0.760 |
Why?
|
| Humans | 160 | 2023 | 261506 | 0.750 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 1 | 2022 | 324 | 0.630 |
Why?
|
| Early Detection of Cancer | 4 | 2023 | 1258 | 0.620 |
Why?
|
| Heart Neoplasms | 3 | 2018 | 214 | 0.620 |
Why?
|
| Periodicals as Topic | 1 | 2021 | 338 | 0.600 |
Why?
|
| Radiology Information Systems | 1 | 2018 | 114 | 0.580 |
Why?
|
| Bronchial Neoplasms | 1 | 2017 | 79 | 0.580 |
Why?
|
| Thymus Neoplasms | 6 | 2022 | 400 | 0.570 |
Why?
|
| Bone Cements | 2 | 2015 | 45 | 0.570 |
Why?
|
| Mass Screening | 4 | 2022 | 1509 | 0.540 |
Why?
|
| Magnetic Resonance Imaging | 13 | 2023 | 7702 | 0.540 |
Why?
|
| Radiotherapy | 5 | 2017 | 1824 | 0.530 |
Why?
|
| Heart Diseases | 1 | 2022 | 732 | 0.530 |
Why?
|
| Thoracic Diseases | 1 | 2015 | 31 | 0.510 |
Why?
|
| Lymphatic Diseases | 2 | 2013 | 128 | 0.500 |
Why?
|
| Thymoma | 4 | 2022 | 246 | 0.490 |
Why?
|
| Artifacts | 10 | 2021 | 532 | 0.490 |
Why?
|
| Tomography, Spiral Computed | 3 | 2010 | 133 | 0.480 |
Why?
|
| Pericardial Effusion | 1 | 2013 | 118 | 0.440 |
Why?
|
| False Positive Reactions | 8 | 2015 | 355 | 0.430 |
Why?
|
| Contrast Media | 12 | 2015 | 1472 | 0.420 |
Why?
|
| Adipose Tissue, Brown | 3 | 2013 | 112 | 0.410 |
Why?
|
| Dyspnea | 1 | 2015 | 416 | 0.410 |
Why?
|
| Lymphatic Metastasis | 12 | 2019 | 4844 | 0.410 |
Why?
|
| Perfusion Imaging | 1 | 2011 | 30 | 0.400 |
Why?
|
| Immunotherapy | 7 | 2022 | 3341 | 0.390 |
Why?
|
| Pneumonia | 5 | 2022 | 751 | 0.370 |
Why?
|
| Pleura | 3 | 2022 | 127 | 0.360 |
Why?
|
| Antineoplastic Agents | 8 | 2018 | 14289 | 0.360 |
Why?
|
| Pulmonary Artery | 3 | 2020 | 499 | 0.350 |
Why?
|
| Sensitivity and Specificity | 15 | 2019 | 4971 | 0.310 |
Why?
|
| Image Processing, Computer-Assisted | 4 | 2009 | 1648 | 0.300 |
Why?
|
| Vocal Cord Paralysis | 2 | 2006 | 82 | 0.290 |
Why?
|
| Esophageal Neoplasms | 8 | 2022 | 3168 | 0.290 |
Why?
|
| Digestive System Diseases | 2 | 2018 | 35 | 0.280 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2017 | 5437 | 0.270 |
Why?
|
| Mycobacterium avium | 1 | 2005 | 22 | 0.270 |
Why?
|
| Mycobacterium avium Complex | 1 | 2005 | 29 | 0.270 |
Why?
|
| Lung Diseases, Fungal | 3 | 2015 | 124 | 0.270 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 1 | 2005 | 31 | 0.270 |
Why?
|
| Male | 60 | 2021 | 123000 | 0.260 |
Why?
|
| Carcinoma, Small Cell | 1 | 2008 | 408 | 0.260 |
Why?
|
| Aged | 46 | 2021 | 70117 | 0.260 |
Why?
|
| Middle Aged | 52 | 2021 | 86204 | 0.260 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2022 | 519 | 0.260 |
Why?
|
| Multiple Pulmonary Nodules | 2 | 2017 | 59 | 0.250 |
Why?
|
| Histoplasma | 1 | 2004 | 32 | 0.250 |
Why?
|
| Central Nervous System Fungal Infections | 1 | 2004 | 19 | 0.250 |
Why?
|
| Lymphadenitis | 1 | 2004 | 39 | 0.250 |
Why?
|
| Radiation Injuries | 4 | 2021 | 1411 | 0.250 |
Why?
|
| Parietal Lobe | 1 | 2004 | 66 | 0.250 |
Why?
|
| Histoplasmosis | 1 | 2004 | 74 | 0.240 |
Why?
|
| Hematologic Neoplasms | 4 | 2022 | 1870 | 0.240 |
Why?
|
| Head and Neck Neoplasms | 4 | 2017 | 3976 | 0.240 |
Why?
|
| Radiography | 8 | 2018 | 1904 | 0.240 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2022 | 406 | 0.240 |
Why?
|
| Adult | 44 | 2021 | 77950 | 0.240 |
Why?
|
| Epilepsy, Generalized | 1 | 2004 | 71 | 0.240 |
Why?
|
| Polytetrafluoroethylene | 1 | 2004 | 113 | 0.230 |
Why?
|
| Female | 58 | 2021 | 141928 | 0.230 |
Why?
|
| Postoperative Complications | 5 | 2021 | 5542 | 0.220 |
Why?
|
| Radiologists | 3 | 2022 | 163 | 0.220 |
Why?
|
| Neoplasms | 10 | 2020 | 15193 | 0.210 |
Why?
|
| Pulmonary Veins | 1 | 2004 | 174 | 0.210 |
Why?
|
| Hemosiderin | 1 | 2021 | 6 | 0.210 |
Why?
|
| Methemoglobin | 1 | 2021 | 9 | 0.210 |
Why?
|
| Image Enhancement | 2 | 2007 | 561 | 0.210 |
Why?
|
| Respiratory Tract Neoplasms | 1 | 2021 | 37 | 0.200 |
Why?
|
| Incidental Findings | 2 | 2018 | 272 | 0.200 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2017 | 1248 | 0.200 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 2195 | 0.200 |
Why?
|
| ErbB Receptors | 3 | 2018 | 2295 | 0.190 |
Why?
|
| Laryngeal Neoplasms | 1 | 2004 | 518 | 0.190 |
Why?
|
| Carotid Arteries | 1 | 2021 | 240 | 0.180 |
Why?
|
| Bevacizumab | 4 | 2018 | 938 | 0.180 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2021 | 160 | 0.180 |
Why?
|
| Angiography | 2 | 2022 | 360 | 0.170 |
Why?
|
| Fibroma | 1 | 2000 | 85 | 0.170 |
Why?
|
| Radiographic Image Enhancement | 4 | 2016 | 402 | 0.170 |
Why?
|
| Tuberculosis | 1 | 2005 | 548 | 0.170 |
Why?
|
| Airway Obstruction | 1 | 2021 | 261 | 0.160 |
Why?
|
| Machine Learning | 1 | 2021 | 319 | 0.160 |
Why?
|
| Mycoses | 1 | 2022 | 386 | 0.160 |
Why?
|
| Multidetector Computed Tomography | 2 | 2017 | 150 | 0.160 |
Why?
|
| Leukemia, Lymphoid | 1 | 2019 | 276 | 0.160 |
Why?
|
| Radiography, Dual-Energy Scanned Projection | 1 | 2018 | 54 | 0.160 |
Why?
|
| Arginine Vasopressin | 1 | 2018 | 60 | 0.160 |
Why?
|
| Erlotinib Hydrochloride | 2 | 2018 | 388 | 0.160 |
Why?
|
| Colonic Diseases | 1 | 1998 | 71 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 598 | 0.150 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 92 | 0.150 |
Why?
|
| Vascular Diseases | 2 | 2016 | 246 | 0.150 |
Why?
|
| Legionellosis | 1 | 2016 | 17 | 0.150 |
Why?
|
| Pulmonary Eosinophilia | 1 | 2016 | 13 | 0.140 |
Why?
|
| Opportunistic Infections | 1 | 2018 | 223 | 0.140 |
Why?
|
| Hemorrhage | 1 | 2021 | 712 | 0.140 |
Why?
|
| Glucose-6-Phosphate | 2 | 2006 | 14 | 0.140 |
Why?
|
| Blood Vessels | 2 | 2015 | 217 | 0.140 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2016 | 26 | 0.140 |
Why?
|
| Aspergillosis, Allergic Bronchopulmonary | 1 | 2016 | 34 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2022 | 6550 | 0.140 |
Why?
|
| Lymph Nodes | 4 | 2018 | 2967 | 0.140 |
Why?
|
| Mouth Neoplasms | 1 | 2021 | 713 | 0.130 |
Why?
|
| Adenocarcinoma | 6 | 2014 | 7789 | 0.130 |
Why?
|
| Retrospective Studies | 22 | 2023 | 37905 | 0.130 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 29902 | 0.130 |
Why?
|
| Fiducial Markers | 1 | 2016 | 96 | 0.130 |
Why?
|
| Hyperparathyroidism | 2 | 2006 | 93 | 0.130 |
Why?
|
| Pneumonia, Bacterial | 1 | 2016 | 130 | 0.130 |
Why?
|
| Pulmonary Alveoli | 1 | 2016 | 208 | 0.130 |
Why?
|
| Esophagus | 2 | 2018 | 553 | 0.130 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 403 | 0.130 |
Why?
|
| Pneumonectomy | 2 | 2018 | 831 | 0.130 |
Why?
|
| Molecular Targeted Therapy | 2 | 2018 | 2330 | 0.130 |
Why?
|
| Enoxaparin | 1 | 2015 | 66 | 0.130 |
Why?
|
| Muscle, Skeletal | 3 | 2007 | 1270 | 0.120 |
Why?
|
| Gonadal Disorders | 1 | 2013 | 8 | 0.120 |
Why?
|
| Urologic Diseases | 1 | 2014 | 78 | 0.120 |
Why?
|
| Muscle, Striated | 1 | 2013 | 14 | 0.120 |
Why?
|
| Thrombosis | 1 | 2020 | 781 | 0.120 |
Why?
|
| Leukemia, Myeloid | 1 | 2019 | 941 | 0.120 |
Why?
|
| Radiosurgery | 1 | 2023 | 1330 | 0.120 |
Why?
|
| Heart | 3 | 2018 | 1223 | 0.120 |
Why?
|
| Warfarin | 1 | 2015 | 152 | 0.120 |
Why?
|
| Respiratory Tract Fistula | 1 | 2013 | 33 | 0.120 |
Why?
|
| Empyema | 1 | 2013 | 28 | 0.120 |
Why?
|
| Bronchial Fistula | 1 | 2013 | 37 | 0.120 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2016 | 304 | 0.110 |
Why?
|
| Pulmonary Edema | 1 | 2013 | 80 | 0.110 |
Why?
|
| Pleural Diseases | 1 | 2013 | 57 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 1819 | 0.110 |
Why?
|
| Research Design | 1 | 2010 | 1544 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2021 | 1350 | 0.110 |
Why?
|
| Neoplasm Metastasis | 5 | 2018 | 5112 | 0.110 |
Why?
|
| Cancer Care Facilities | 1 | 2017 | 884 | 0.110 |
Why?
|
| Thoracotomy | 1 | 2013 | 220 | 0.100 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2022 | 1763 | 0.100 |
Why?
|
| United States | 4 | 2022 | 15433 | 0.100 |
Why?
|
| Colonic Neoplasms | 2 | 2007 | 1390 | 0.100 |
Why?
|
| Risk Factors | 7 | 2019 | 17523 | 0.100 |
Why?
|
| Follow-Up Studies | 8 | 2023 | 14889 | 0.100 |
Why?
|
| Referral and Consultation | 1 | 2017 | 899 | 0.100 |
Why?
|
| Smoking | 1 | 2010 | 2440 | 0.100 |
Why?
|
| Vulvar Neoplasms | 1 | 2013 | 236 | 0.100 |
Why?
|
| Carcinoma | 1 | 2022 | 2578 | 0.100 |
Why?
|
| Whole Body Imaging | 1 | 2011 | 114 | 0.090 |
Why?
|
| Treatment Outcome | 13 | 2021 | 32848 | 0.090 |
Why?
|
| Pneumonia, Lipid | 1 | 2010 | 5 | 0.090 |
Why?
|
| Thyroid Gland | 2 | 2018 | 355 | 0.090 |
Why?
|
| Tissue Extracts | 1 | 2010 | 48 | 0.090 |
Why?
|
| Prognosis | 8 | 2022 | 21713 | 0.090 |
Why?
|
| Combined Modality Therapy | 7 | 2021 | 8865 | 0.090 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2009 | 20 | 0.090 |
Why?
|
| Invasive Pulmonary Aspergillosis | 1 | 2010 | 47 | 0.090 |
Why?
|
| Quality Control | 2 | 2017 | 457 | 0.090 |
Why?
|
| Venous Thrombosis | 1 | 2013 | 384 | 0.090 |
Why?
|
| Precision Medicine | 1 | 2017 | 1154 | 0.090 |
Why?
|
| Iatrogenic Disease | 2 | 2014 | 183 | 0.090 |
Why?
|
| Reproducibility of Results | 6 | 2021 | 6009 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2011 | 4892 | 0.090 |
Why?
|
| Anticoagulants | 1 | 2015 | 787 | 0.080 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 2 | 2008 | 74 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 4757 | 0.080 |
Why?
|
| Zygomycosis | 1 | 2008 | 31 | 0.080 |
Why?
|
| Fusarium | 1 | 2008 | 50 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2390 | 0.080 |
Why?
|
| Subtraction Technique | 2 | 2006 | 141 | 0.080 |
Why?
|
| Survival Rate | 6 | 2013 | 12221 | 0.080 |
Why?
|
| Parathyroidectomy | 2 | 2006 | 203 | 0.080 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2004 | 1533 | 0.080 |
Why?
|
| Adolescent | 6 | 2018 | 31252 | 0.080 |
Why?
|
| Adipose Tissue | 2 | 2006 | 769 | 0.080 |
Why?
|
| Observer Variation | 4 | 2017 | 671 | 0.080 |
Why?
|
| Pyridines | 2 | 2017 | 1244 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2012 | 589 | 0.070 |
Why?
|
| Respiration | 2 | 2006 | 447 | 0.070 |
Why?
|
| Liver | 2 | 2022 | 2961 | 0.070 |
Why?
|
| Hyperventilation | 1 | 2006 | 19 | 0.070 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2006 | 88 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2012 | 691 | 0.070 |
Why?
|
| Respiratory Muscles | 1 | 2006 | 27 | 0.070 |
Why?
|
| Acne Vulgaris | 1 | 2006 | 47 | 0.070 |
Why?
|
| Arteriovenous Fistula | 1 | 2007 | 92 | 0.070 |
Why?
|
| Pleurodesis | 1 | 2006 | 71 | 0.070 |
Why?
|
| Ulcer | 1 | 2006 | 78 | 0.070 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2006 | 69 | 0.070 |
Why?
|
| Esophageal Diseases | 1 | 2006 | 69 | 0.070 |
Why?
|
| Proton Therapy | 1 | 2016 | 1577 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2010 | 15862 | 0.070 |
Why?
|
| Molecular Epidemiology | 1 | 2006 | 246 | 0.060 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2004 | 22 | 0.060 |
Why?
|
| Kyphosis | 1 | 2004 | 43 | 0.060 |
Why?
|
| Enterocolitis, Pseudomembranous | 2 | 2012 | 111 | 0.060 |
Why?
|
| Technology Assessment, Biomedical | 1 | 2004 | 59 | 0.060 |
Why?
|
| Pancreatitis | 2 | 2020 | 267 | 0.060 |
Why?
|
| Protein Kinase C | 1 | 2006 | 396 | 0.060 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 185 | 0.060 |
Why?
|
| Sesquiterpenes | 1 | 2004 | 68 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2023 | 12873 | 0.060 |
Why?
|
| Injections, Intralesional | 1 | 2004 | 164 | 0.060 |
Why?
|
| Mass Chest X-Ray | 1 | 2003 | 4 | 0.060 |
Why?
|
| Multiple Endocrine Neoplasia Type 1 | 1 | 2005 | 141 | 0.060 |
Why?
|
| Piperidines | 1 | 2009 | 1035 | 0.060 |
Why?
|
| Immunocompromised Host | 2 | 2022 | 698 | 0.060 |
Why?
|
| Spine | 1 | 2004 | 293 | 0.060 |
Why?
|
| Reference Values | 1 | 2005 | 1099 | 0.060 |
Why?
|
| Biopsy, Needle | 3 | 2018 | 1363 | 0.050 |
Why?
|
| Organoplatinum Compounds | 1 | 2005 | 702 | 0.050 |
Why?
|
| Seasons | 1 | 2023 | 340 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2004 | 1323 | 0.050 |
Why?
|
| Ischemic Attack, Transient | 1 | 2021 | 55 | 0.050 |
Why?
|
| Ultrasonography | 3 | 2009 | 1863 | 0.050 |
Why?
|
| Public Opinion | 1 | 2022 | 83 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10035 | 0.050 |
Why?
|
| Thyroiditis | 1 | 2020 | 18 | 0.050 |
Why?
|
| Lymphoma | 1 | 2010 | 1467 | 0.050 |
Why?
|
| Biopsy | 3 | 2014 | 3443 | 0.050 |
Why?
|
| Indoles | 1 | 2006 | 1009 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 341 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 2403 | 0.050 |
Why?
|
| Surgical Flaps | 1 | 2007 | 927 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2005 | 1244 | 0.050 |
Why?
|
| Pericarditis | 1 | 2020 | 61 | 0.050 |
Why?
|
| Adrenal Gland Diseases | 1 | 2020 | 72 | 0.050 |
Why?
|
| Mouth | 1 | 2021 | 122 | 0.050 |
Why?
|
| Hepatitis | 1 | 2020 | 93 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2006 | 1450 | 0.050 |
Why?
|
| Endpoint Determination | 1 | 2010 | 176 | 0.050 |
Why?
|
| Myocardium | 1 | 2006 | 1313 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2007 | 1303 | 0.040 |
Why?
|
| Sarcoidosis | 1 | 2020 | 112 | 0.040 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2010 | 226 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2007 | 3981 | 0.040 |
Why?
|
| Encephalitis | 1 | 2020 | 143 | 0.040 |
Why?
|
| Pneumothorax | 1 | 2000 | 153 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2010 | 298 | 0.040 |
Why?
|
| Postoperative Period | 1 | 2021 | 665 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 406 | 0.040 |
Why?
|
| Colitis, Ischemic | 1 | 1998 | 5 | 0.040 |
Why?
|
| Diverticulitis, Colonic | 1 | 1998 | 11 | 0.040 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 7548 | 0.040 |
Why?
|
| Myocarditis | 1 | 2020 | 190 | 0.040 |
Why?
|
| Prevalence | 2 | 2018 | 3260 | 0.040 |
Why?
|
| Bone Marrow | 1 | 2006 | 2358 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2010 | 2231 | 0.040 |
Why?
|
| Mutation | 1 | 2018 | 15179 | 0.040 |
Why?
|
| Liver Diseases | 2 | 2014 | 574 | 0.040 |
Why?
|
| Catheterization, Central Venous | 1 | 2000 | 354 | 0.040 |
Why?
|
| Colitis | 1 | 2020 | 340 | 0.040 |
Why?
|
| Quinazolines | 2 | 2017 | 923 | 0.040 |
Why?
|
| Ascites | 1 | 1998 | 198 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2006 | 2359 | 0.040 |
Why?
|
| Doxorubicin | 2 | 2004 | 3005 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2004 | 1996 | 0.040 |
Why?
|
| Legionella | 1 | 2016 | 18 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2000 | 726 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2023 | 2803 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2010 | 1014 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2021 | 2292 | 0.030 |
Why?
|
| Ireland | 1 | 2015 | 30 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2006 | 1664 | 0.030 |
Why?
|
| Metals | 1 | 2016 | 155 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2009 | 5178 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 1998 | 268 | 0.030 |
Why?
|
| Survival Analysis | 3 | 2018 | 9180 | 0.030 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 324 | 0.030 |
Why?
|
| Neoadjuvant Therapy | 2 | 2007 | 4975 | 0.030 |
Why?
|
| Foreign Bodies | 1 | 2016 | 145 | 0.030 |
Why?
|
| Intestine, Small | 1 | 1998 | 499 | 0.030 |
Why?
|
| Child | 3 | 2022 | 29154 | 0.030 |
Why?
|
| Crohn Disease | 1 | 1998 | 351 | 0.030 |
Why?
|
| Thyroid Neoplasms | 1 | 2005 | 1866 | 0.030 |
Why?
|
| ROC Curve | 1 | 2017 | 1183 | 0.030 |
Why?
|
| Splenic Diseases | 1 | 2014 | 56 | 0.030 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 295 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2017 | 4988 | 0.030 |
Why?
|
| Child, Preschool | 2 | 2014 | 16273 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2014 | 121 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2006 | 4938 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 3719 | 0.030 |
Why?
|
| Stroke | 1 | 2021 | 1144 | 0.030 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4849 | 0.030 |
Why?
|
| Pneumatosis Cystoides Intestinalis | 1 | 2012 | 16 | 0.030 |
Why?
|
| Abdomen | 1 | 2014 | 332 | 0.030 |
Why?
|
| Pelvis | 1 | 2014 | 362 | 0.030 |
Why?
|
| Ileus | 1 | 2012 | 27 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2008 | 925 | 0.030 |
Why?
|
| Neoplasm, Residual | 2 | 2009 | 1656 | 0.030 |
Why?
|
| Esophagectomy | 2 | 2007 | 911 | 0.030 |
Why?
|
| Sarcoma | 1 | 2002 | 1725 | 0.030 |
Why?
|
| Hypertension, Pulmonary | 1 | 2016 | 462 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 1085 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 2864 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2018 | 6869 | 0.020 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 1271 | 0.020 |
Why?
|
| Infusions, Intravenous | 2 | 2005 | 1382 | 0.020 |
Why?
|
| Respiratory Aspiration | 1 | 2010 | 30 | 0.020 |
Why?
|
| Cartilage | 1 | 2010 | 128 | 0.020 |
Why?
|
| Drug Administration Schedule | 2 | 2006 | 3472 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 4654 | 0.020 |
Why?
|
| Algorithms | 1 | 2021 | 3890 | 0.020 |
Why?
|
| Gastroenteritis | 1 | 2012 | 300 | 0.020 |
Why?
|
| Melanoma | 1 | 2006 | 5317 | 0.020 |
Why?
|
| Neoplasm Grading | 1 | 2013 | 1742 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2017 | 1471 | 0.020 |
Why?
|
| Fibrosis | 1 | 2012 | 793 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 1946 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2010 | 5687 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2009 | 726 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 94 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2012 | 3251 | 0.020 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2009 | 192 | 0.020 |
Why?
|
| Neutropenia | 1 | 2012 | 968 | 0.020 |
Why?
|
| Biological Products | 1 | 2010 | 274 | 0.020 |
Why?
|
| Protein Kinase C beta | 1 | 2006 | 35 | 0.020 |
Why?
|
| Back | 1 | 2006 | 45 | 0.020 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2007 | 164 | 0.020 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2006 | 121 | 0.020 |
Why?
|
| HIV Infections | 1 | 2019 | 2134 | 0.020 |
Why?
|
| Young Adult | 2 | 2018 | 21445 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2009 | 690 | 0.020 |
Why?
|
| Parathyroid Glands | 1 | 2006 | 127 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2009 | 551 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2007 | 660 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2009 | 1290 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2006 | 305 | 0.020 |
Why?
|
| Disease Progression | 2 | 2009 | 6682 | 0.020 |
Why?
|
| Recurrence | 1 | 2013 | 4758 | 0.020 |
Why?
|
| Bronchography | 1 | 2004 | 25 | 0.020 |
Why?
|
| Parathyroid Neoplasms | 1 | 2006 | 185 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2004 | 38 | 0.020 |
Why?
|
| Heart Failure | 1 | 1998 | 2516 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2006 | 291 | 0.020 |
Why?
|
| Thoracoscopy | 1 | 2005 | 101 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2010 | 2588 | 0.020 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2005 | 169 | 0.020 |
Why?
|
| Thymectomy | 1 | 2004 | 79 | 0.020 |
Why?
|
| Drug Carriers | 1 | 2005 | 327 | 0.010 |
Why?
|
| Tumor Burden | 1 | 2009 | 1987 | 0.010 |
Why?
|
| Probability | 1 | 2005 | 866 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2006 | 703 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2005 | 553 | 0.010 |
Why?
|
| Liposomes | 1 | 2005 | 684 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 1546 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4298 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2006 | 1544 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2004 | 980 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 3890 | 0.010 |
Why?
|
| Exons | 1 | 2006 | 1328 | 0.010 |
Why?
|
| Embolization, Therapeutic | 1 | 2007 | 551 | 0.010 |
Why?
|
| Carboplatin | 1 | 2004 | 823 | 0.010 |
Why?
|
| Subclavian Vein | 1 | 2000 | 35 | 0.010 |
Why?
|
| Thoracostomy | 1 | 2000 | 43 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 6207 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2006 | 1529 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2006 | 3033 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 2437 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2004 | 795 | 0.010 |
Why?
|
| Catheterization | 1 | 2000 | 410 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10001 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 3001 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 2432 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 2000 | 554 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2005 | 2518 | 0.010 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2002 | 882 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2002 | 929 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2005 | 4367 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 8873 | 0.010 |
Why?
|